Angiotensin-II receptor blockers for hypertension and heart failure: Quality of life and outcomes

Managed Care Interface

Volumn 18, Issue 2, 2005, Pages 47-54

  Weber, Michael A ^a,b  

^a Department of Medicine ^*  (United States)

^b Downstate Health Sciences University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; METHYLDOPA; NITRENDIPINE; PROPRANOLOL; VALSARTAN;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; COUGHING; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EXERCISE TOLERANCE; FLUSHING; GYNECOMASTIA; HEADACHE; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; OUTCOMES RESEARCH; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; TREATMENT WITHDRAWAL; ARTICLE; CONGESTIVE HEART FAILURE; TREATMENT OUTCOME; UNITED STATES;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED STATES;

EID: 15944401380     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Heart Disease and Stroke Statistics - 2004 Update (bulletin). Dallas, American Heart Association, 2003.
2. Sloan JA, Cella D, Frost M, et al: Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 2002;77:367-370.
3. Anand IS, Florea VG, Fisher L: Surrogate end points in heart failure. J Am Coll Cardiol 2002;39:1414-1421.
4. Al-Kaade S, Hauptman PJ: Health-related quality of life measurement in heart failure: Challenges for the new millennium. J Card Fail 2001;7:194-201.
5. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22:1527-1560.
6. Konstam V, Salem D, Pouleur H, et al, for the SOLVD Investigators: Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. Am J Cardiol 1996;78:890-895.
7. Cohn JN: Exercise tolerance as a guide to therapeutic efficacy for heart failure: The potential for angiotensin receptor blockers. Circulation 1999;100:2208-2209.
8. Wiklund E, Halling K, Ryden-Bergsten T, et al: Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) Study. Blood Press 1997;6:357-364.
9. Dahlöf B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
10. Lewis EF, Johnson PA, Johnson W, et al: Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001;20:1016-1024.
11. Kusek JW, Greene P, Wang S-R, et al: Cross-sectional study of health-related quality of life in African Americans with chronic renal insufficiency. Am J Kidney Dis 2002;39:513-524.
12. Fletcher AE, Bulpitt CJ, Tuomilehto J, et al: Quality of life of elderly patients with isolated systolic hypertension: Baseline data from the Syst-Eur Trial. J Hypertens 1998;16:1117-1124.
13. Juenger J, Schellberg D, Kraemer S, et al: Health-related quality of life in patients with congestive heart failure: Comparison with other chronic diseases and relation to functional variables. Heart 2002;87:235-241.
14. Murberg TA, Bru E, Aarsland T, et al: Functional status and depression among men and women with congestive heart failure. Int J Psychiatry Med 1998;28:273-291.
15. Riedinger MS, Dracup KA, Brecht M-L, et al: Predictors of quality of life in women with heart failure. J Heart Lung Transplant 2000;19:598-608.
16. Riedinger MS, Dracup KA, Brecht M-L, et al: Quality of life in patients with heart failure: Do gender differences exist? Heart Lung 2001;30:105-116.
17. Rector TS, Kubo SH, Cohn JN: Patients' self-assessment of their congestive heart failure, II. Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Fail 1987;3:198-209.
18. Green CP, Porter CB, Bresnahan DR, et al: Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-1255.
19. Bulpitt CJ: Quality of life with ACE inhibitors in chronic heart failure. J Cardiovasc Pharmacol 1996;27(suppl 2):31-35.
20. Bremner AD: Antihypertensive medication and quality of life: Silent treatment of a silent killer? Cardiovasc Drugs Ther 2002; 16:353-364.
21. Croog SH, Levine S, Testa MA, et al: The effects of antihyper tensive therapy on the quality of life. N Engl J Med 1986;314:1657-1664.
22. Testa MA, Anderson RB, Nackley JF, et al, for the Quality-of-Life Hypertension Study Group: Quality of life and antihypertensive therapy in men: A comparison of captopril with enalapril. N Engl J Med 1993;328:907-913.
23. Hollenberg NK, Williams GH, Anderson R: Medical therapy, symptoms and the distress they cause. Arch Intern Med 2000; 160:1477-1483.
24. Applegate WB: Quality of life during antihypertensive treatment: Lessons from the Systolic Hypertension in the Elderly Program. Am J Hypertens 1998;11(suppl):57-61.
25. Weir MR, Prisant LM, Papademetriou V, et al: Antihypertensive therapy and quality of life: Influence of blood pressure reduction, adverse events, and prior antihypertensive therapy. Am J Hypertens 1996;9:854-859.
26. Breeze E, Rake EC, Donoghue MD, et al: Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension, J Hum Hypertens 2001;15:857-862.
27. Rake EC, Breeze E, Fletcher AE: Quality of life and cough on antihypertensive treatment: A randomised trial of eprosartan, enalapril and placebo. J Hum Hypertens 2001;15:863-867.
28. Oparil S: Are there meaningful differences in blood pressure control with current antihypertensive agents? Am J Hypertens 2002;15:(suppl)14-21.
29. Fogari R, Zoppi A, Poletti L, et al: Sexual activity in hypertensive men treated with valsartan or carvedilol: A cross-over study. Am J Hypertens 2001;14:27-31.
30. Fogari R, Zoppi A, Corradi L, et al: Sexual function in hypertensive males treated with lisinopril or atenolol: A cross-over study. Am J Hypertens 1998;11:1244-1247.
31. Duncan LE, Lewis C, Jenkins P, et al: Does hypertension and its pharmacotherapy affect the quality of sexual function in women? Am J Hypertens 2000;13:640-647.
32. Burnier M: Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-912.
33. Fletcher AE, Bulpitt CJ, Lutgarde T, et al: Quality of life on randomized treatment for isolated systolic hypertension: Results from the Syst-Eur Trial. J Hypertens 2002;20:2069-2079.
34. Bulpitt CJ, Beckett NS, Fletcher AE, et al: Withdrawal from treatment in the Syst-Eur Trial. J Hypertens 2002;20:339-346.
35. Hollenberg NK: Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure. Curr Hypertens Rep 2001;3(suppl 1):25-28.
36. Weber MA, Bakris GL, Neutel JM, et al: Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens 2003;5:322-329.
37. Kjeldsen SE, Julius S, Brunner H, et al: Characteristics of 15,314 patients at high coronary risk: The VALUE Trial. Blood Press 2001;10:1-11.
38. Weber MA: Interrupting the renin-angiotensin system: The role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens 1999;12(suppl):189-194.
39. Roca-Cusachs A, Dalfo A, Badia X, et al: Relation between clinical and therapeutic variables and quality of life in hypertension. J Hypertens 2001;19:1913-1919.
40. Dahlöf B, Lindholm LH, Carney S, et al, for the LOA Study group: Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. J Hypertens 1997;15:1327-1335.
41. Tedesco MA, Ratti G, Mennella S, et al: Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999;12:1130-1134.
42. Lithell H, Hansson L, Skoog I, et al: The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
43. de Gasparo M, Levens N: Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Taxicol 1998;82:257-271.
44. Messerli FH, Weber MA, Brunner HR: Angiotensin II receptor inhibition. Arch Intern Med 1996;156:1957-1965.
45. Pitt B, Segal R, Martinez FA, et al: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
46. Pitt B, Poole-Wilsoii PA, Segal R, et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
47. McKelvie RS, Yusuf S, Pericak D, et al: Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 1999;100:1056-1064.
48. Riegger GAJ, Bouzo H, Petr P, et al: Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan dlexetil. Circulation 1999;100:2224-2230.
49. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
50. Rapezzi C, Tognoni G, Perini GP, et al: Effect of valsartan on quality of life when added to standard treatment for heart failure: Results from Val-HeFT (abstract). Eur Heart J 2001;22 (suppl):535.
51. Carson P, Tognoni G, Cohn JN: Effect of valsartan on hospitalization: Results from Val-HeFT. J Card Fail 2003;9:164-171.
52. Maggioni AP, Anand I, Gottlieb SO, et al: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-1421.
53. Diovan, in Physicians' Desk Reference. Ed. 56. Montvale, NJ, Medical Economics, 2002; 2337-2342.
54. Smith DG, Cerulli A, Frech FF: Heart failure cost-savings with valsartan (abstract). Am J Hypertens 2003;16 (suppl):92A.